[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363043-105":59,"doc-detail-363043-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","tumor-targeted-exosomal-delivery-of-celastrol-for-enhanced-therapeutic-efficacy-in-nsclc","Tumor-targeted Exosomal Delivery of Celastrol for Enhanced Therapeutic Efficacy in NSCLC","","Non-small cell lung cancer (NSCLC) remains difficult to treat due to limited options, drug resistance, and treatment-related toxicity. The study develops an exosome-based, tumor-targeted delivery system for celastrol (CEL), using folate-functionalized exosomes (FA-ExoCEL). Exosomes were isolated from bovine colostrum, characterized, loaded with CEL, and validated biochemically. Anticancer activity was evaluated in NSCLC cells via migration, uptake, and colony formation, with transcriptomic and protein analyses. In orthotopic mouse models, FA-ExoCEL achieved ~80–90% tumor inhibition with efficient oral uptake and no observed systemic toxicity, and CEL showed synergy with paclitaxel.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tumor-targeted-exosomal-delivery-of-celastrol-for-enhanced-therapeutic-efficacy-in-nsclc/363043/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tumor-targeted-exosomal-delivery-of-celastrol-for-enhanced-therapeutic-efficacy-in-nsclc/363043.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is targeted exosomal delivery considered for NSCLC treatment?","Question",{"text":113,"@type":114},"NSCLC has limited effective therapies and frequent drug resistance and toxicity. Exosomes are explored because they can deliver therapeutic agents in a targeted manner, and oral delivery may improve safety and compliance.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were exosomes and celastrol formulations prepared and validated?",{"text":118,"@type":114},"Exosomes were isolated from bovine colostrum and characterized for size, polydispersity index, and surface charge. CEL was loaded onto exosomes, and folic acid functionalization produced FA-ExoCEL, which was validated using fluorescence quenching and protease sensitivity assays.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key findings in cell and animal models?",{"text":122,"@type":114},"ExoCEL and FA-ExoCEL inhibited NSCLC cell proliferation and migration, reversed TGF-β–induced EMT, and restored epithelial markers. In orthotopic lung tumor models, FA-ExoCEL produced approximately 80–90% tumor inhibition with efficient gastrointestinal uptake and no observed systemic toxicity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},363043,1790273367,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Theranostics 2026, Vol. 16, Issue 10 5125  \nIvyspring  \nInternational Publisher  \nTheranostics  \n2026; 16(10): 5125-5149. doi: 10.7150/thno.125096  \nResearch Paper  \nTumor-targeted Exosomal Delivery of Celastrol for Enhanced Therapeutic Efficacy in NSCLC  \nDisha Nagesh Moholkar1,3\\#, Raghuram Kandimalla1,3\\#, Mohd Saeed4, Yaseera Arif1, Neha Tyagi1, Richa Singhal2,5, Al-Hassan Kyakulaga1,3, Amir Saeed6, Margaret Wallen7, Ramesh Gupta1,3 and Farrukh Aqil1,2,3􀀍  \n1. Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.  \n2. Department of Medicine, University of Louisville, Louisville, KY 40202, USA.  \n3. Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY 40202, USA.  \n4. Department of Biology College of Sciences, University of Hail, Hail, Saudi Arabia.  \n5. Center for Cardiometabolic Science, University of Louisville, Louisville, KY 40202, USA.  \n6. Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, Hail, Saudi Arabia.  \n7. 3P Biotechnologies Inc., Louisville, KY 40202, USA.  \n\\# Equal contribution as first author.  \n􀀍 Corresponding author: Dr. Farrukh Aqil, 580 S. Preston St, Rm 304B, Louisville, KY 40202, USA; phone: 502 852 7315; fax: 502 852 3842; email: [farrukh.aqil@louisville.edu](farrukh.aqil@louisville.edu).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.09.12; Accepted: 2026.02.07; Published: 2026.03.03  \nAbstract  \nRationale: Non-small cell lung cancer (NSCLC) continues to impose a significant global mortality burden, due to limited therapies, drug resistance, and treatment-related toxicity. Exosomes offer promise for the targeted delivery of therapeutic agents.  \nMethods: Exosomes were isolated from bovine colostrum and characterized for size, polydispersity index, and surface charge. Celastrol (CEL) was loaded onto exosomes (ExoCEL), and Folic Acid (FA)-functionalized exosomes (FA-ExoCEL) and validated using fluorescence quenching and protease sensitivity assay. Anticancer activity was assessed in NSCLC cell lines using colony formation, cell migration and uptake assays. Transcriptomic (RNA-seq) and protein analysis were performed to analyze gene expression changes. Biodistribution, oral uptake and potential toxicity were evaluated in wild-type mice, while oral antitumor efficacy was tested in orthotopic lung tumor models comparing CEL, ExoCEL and FA-ExoCEL. Synergistic activity with paclitaxel was assessed in chemoresistant cells.  \nResults: Exosomes were isolated, characterized and efficiently loaded with CEL. ExoCEL demonstrated superior antiproliferative effects in NSCLC cell lines and enhanced potency in drug-resistant A549TR cells compared to free CEL. ExoCEL significantly inhibited colony formation and cell migration in a dose-dependent manner. RNA Seq and protein analyses showed that CEL and ExoCEL reversed TGF-β–induced EMT, restored epithelial markers, suppressed mesenchymal, oncogenic and extracellular matrix related markers. In orthotopic lung tumor models, FA-ExoCEL achieved approximately 80-90% tumor inhibition, outperforming both free CEL and ExoCEL. Oral delivery of FA-ExoCEL resulted in efficient gastrointestinal uptake, selective tumor targeting, recovery of exosomal markers in circulation and no observed systemic toxicity. CEL exhibited strong synergy with paclitaxel, with exosomal delivery further enhancing paclitaxel efficacy in resistant cells.  \nConclusions: FA-ExoCEL represents a safe, scalable, and effective oral therapeutic strategy for NSCLC. By combining exosome-mediated delivery with folate-targeted tumor accumulation, this platform enhances CEL bioavailability, and improves antitumor efficacy, supporting its ","cbCaihTtrI8ZO2Rk","https://ap.wps.com/l/cbCaihTtrI8ZO2Rk","pdf",6994181,25,"English","# Abstract\n## Rationale\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"Why is targeted exosomal delivery considered for NSCLC treatment?\",\"answer\":\"NSCLC has limited effective therapies and frequent drug resistance and toxicity. Exosomes are explored because they can deliver therapeutic agents in a targeted manner, and oral delivery may improve safety and compliance.\"},{\"question\":\"How were exosomes and celastrol formulations prepared and validated?\",\"answer\":\"Exosomes were isolated from bovine colostrum and characterized for size, polydispersity index, and surface charge. CEL was loaded onto exosomes, and folic acid functionalization produced FA-ExoCEL, which was validated using fluorescence quenching and protease sensitivity assays.\"},{\"question\":\"What were the key findings in cell and animal models?\",\"answer\":\"ExoCEL and FA-ExoCEL inhibited NSCLC cell proliferation and migration, reversed TGF-β–induced EMT, and restored epithelial markers. In orthotopic lung tumor models, FA-ExoCEL produced approximately 80–90% tumor inhibition with efficient gastrointestinal uptake and no observed systemic toxicity.\"}]","Tumor-targeted Exosomal Delivery of Celastrol for Enhanced Therapeutic Efficacy in NSCLC | PDF",1790149761,63,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f582977b42c497bf7b5be38dd0e206e.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d48cb34abf781b54cb3deb252924cefc.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4bd504b3ac389cfabf4d5b5606962ab2.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ccca5a4b110646de71ba03aea5c272cb.webp",980,1268]